0001427570--12-312023Q1953889538851921926487650.021.51.5false0001427570rsls:RepresentativesWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberrsls:PublicOfferingMember2023-02-080001427570rsls:RepresentativesWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMemberrsls:PublicOfferingMember2023-02-080001427570rsls:RepresentativesWarrantsMemberus-gaap:MeasurementInputExpectedTermMemberrsls:PublicOfferingMember2023-02-080001427570rsls:RepresentativesWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMemberrsls:PublicOfferingMember2023-02-080001427570rsls:PreFundedWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberrsls:PublicOfferingMember2023-02-080001427570rsls:PreFundedWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMemberrsls:PublicOfferingMember2023-02-080001427570rsls:PreFundedWarrantsMemberus-gaap:MeasurementInputExpectedTermMemberrsls:PublicOfferingMember2023-02-080001427570rsls:PreFundedWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMemberrsls:PublicOfferingMember2023-02-080001427570rsls:CashlessExerciseMemberus-gaap:MeasurementInputSharePriceMemberrsls:BlackScholesModelMember2023-02-080001427570rsls:CashlessExerciseMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberrsls:BlackScholesModelMember2023-02-080001427570rsls:CashlessExerciseMemberus-gaap:MeasurementInputPriceVolatilityMemberrsls:BlackScholesModelMember2023-02-080001427570rsls:CashlessExerciseMemberus-gaap:MeasurementInputExpectedTermMemberrsls:BlackScholesModelMember2023-02-080001427570rsls:CashlessExerciseMemberus-gaap:MeasurementInputExpectedDividendRateMemberrsls:BlackScholesModelMember2023-02-080001427570rsls:CashlessExerciseMemberus-gaap:MeasurementInputExercisePriceMemberrsls:BlackScholesModelMember2023-02-080001427570rsls:CashExerciseMemberus-gaap:MeasurementInputSharePriceMemberrsls:BlackScholesModelMember2023-02-080001427570rsls:CashExerciseMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberrsls:BlackScholesModelMember2023-02-080001427570rsls:CashExerciseMemberus-gaap:MeasurementInputPriceVolatilityMemberrsls:BlackScholesModelMember2023-02-080001427570rsls:CashExerciseMemberus-gaap:MeasurementInputExpectedTermMemberrsls:BlackScholesModelMember2023-02-080001427570rsls:CashExerciseMemberus-gaap:MeasurementInputExpectedDividendRateMemberrsls:BlackScholesModelMember2023-02-080001427570rsls:CashExerciseMemberus-gaap:MeasurementInputExercisePriceMemberrsls:BlackScholesModelMember2023-02-080001427570us-gaap:CommonStockMember2022-01-012022-03-310001427570us-gaap:SubsequentEventMemberrsls:RegisteredDirectOfferingMember2023-04-202023-04-200001427570rsls:PrivatePlacementWarrantsMemberus-gaap:SubsequentEventMember2023-04-202023-04-2000014275702022-12-232022-12-230001427570us-gaap:RetainedEarningsMember2023-03-310001427570us-gaap:AdditionalPaidInCapitalMember2023-03-310001427570us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001427570us-gaap:RetainedEarningsMember2022-12-310001427570us-gaap:AdditionalPaidInCapitalMember2022-12-310001427570us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001427570us-gaap:RetainedEarningsMember2022-03-310001427570us-gaap:AdditionalPaidInCapitalMember2022-03-310001427570us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001427570us-gaap:RetainedEarningsMember2021-12-310001427570us-gaap:AdditionalPaidInCapitalMember2021-12-310001427570us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001427570rsls:SeriesCConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-03-310001427570us-gaap:CommonStockMember2023-03-310001427570rsls:SeriesCConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-12-310001427570us-gaap:CommonStockMember2022-12-310001427570rsls:SeriesCConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-03-310001427570us-gaap:CommonStockMember2022-03-310001427570rsls:SeriesCConvertiblePreferredStockMemberus-gaap:PreferredStockMember2021-12-310001427570us-gaap:CommonStockMember2021-12-310001427570us-gaap:EmployeeStockOptionMember2022-12-310001427570us-gaap:EmployeeStockOptionMember2022-03-310001427570us-gaap:RestrictedStockUnitsRSUMember2022-12-310001427570us-gaap:NonUsMember2023-01-012023-03-310001427570srt:EuropeMember2023-01-012023-03-310001427570rsls:ReshapeVestAndDiabetesBlocStimNeuromodulationProductsMember2023-01-012023-03-310001427570rsls:ObalonTherapeuticsInc.Member2023-01-012023-03-310001427570country:US2023-01-012023-03-310001427570country:AU2023-01-012023-03-310001427570us-gaap:NonUsMember2022-01-012022-03-310001427570srt:EuropeMember2022-01-012022-03-310001427570rsls:ReshapeVestAndDiabetesBlocStimNeuromodulationProductsMember2022-01-012022-03-310001427570rsls:ObalonTherapeuticsInc.Member2022-01-012022-03-310001427570country:US2022-01-012022-03-310001427570country:AU2022-01-012022-03-310001427570rsls:PreFundedWarrantsMemberus-gaap:SubsequentEventMember2023-04-202023-04-200001427570rsls:SeriesCConvertiblePreferredStockMember2023-03-310001427570rsls:SeriesCConvertiblePreferredStockMember2022-12-310001427570us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001427570us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001427570us-gaap:RetainedEarningsMember2023-01-012023-03-310001427570us-gaap:RetainedEarningsMember2022-01-012022-03-310001427570rsls:SanClementeOfficeAndWarehouseSpaceMember2023-03-310001427570us-gaap:TrademarksAndTradeNamesMember2023-01-012023-03-310001427570us-gaap:DevelopedTechnologyRightsMember2023-01-012023-03-310001427570srt:MaximumMember2023-01-012023-03-310001427570us-gaap:TrademarksAndTradeNamesMember2022-01-012022-12-310001427570us-gaap:DevelopedTechnologyRightsMember2022-01-012022-12-310001427570us-gaap:TrademarksAndTradeNamesMember2023-03-310001427570us-gaap:DevelopedTechnologyRightsMember2023-03-310001427570us-gaap:TrademarksAndTradeNamesMember2022-12-310001427570us-gaap:DevelopedTechnologyRightsMember2022-12-310001427570rsls:CommonStockPurchaseWarrantsMember2023-03-310001427570rsls:CommonStockPurchaseWarrantsMember2023-02-080001427570us-gaap:EmployeeStockOptionMember2023-03-310001427570us-gaap:RestrictedStockUnitsRSUMember2023-03-310001427570us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001427570us-gaap:SubsequentEventMemberrsls:RegisteredDirectOfferingMember2023-04-200001427570srt:MaximumMemberrsls:AmendedWarrantsMemberus-gaap:SubsequentEventMember2023-04-200001427570rsls:PreFundedWarrantsMemberus-gaap:SubsequentEventMemberrsls:RegisteredDirectOfferingMember2023-04-200001427570us-gaap:OverAllotmentOptionMember2023-02-080001427570rsls:CommonStockWarrantsWithAlternativeCashlessExerciseMemberus-gaap:CommonStockMemberrsls:PublicOfferingMember2023-02-080001427570rsls:PublicWarrantsMemberrsls:PublicOfferingMember2023-02-080001427570us-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2023-04-200001427570rsls:PreFundedWarrantsMemberus-gaap:SubsequentEventMember2023-04-200001427570rsls:AmendedWarrantsMemberus-gaap:SubsequentEventMember2023-04-200001427570us-gaap:SubsequentEventMember2023-04-200001427570rsls:CommonStockWarrantsWithAlternativeCashlessExerciseMemberrsls:PublicOfferingMember2023-02-0800014275702022-03-3100014275702021-12-310001427570rsls:IrvineCaliforniaOfficeAndWarehouseSpaceMember2023-03-130001427570us-gaap:WarrantMember2023-01-012023-03-310001427570us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001427570us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001427570us-gaap:ConvertiblePreferredStockMember2023-01-012023-03-310001427570us-gaap:WarrantMember2022-01-012022-03-310001427570us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001427570us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001427570us-gaap:ConvertiblePreferredStockMember2022-01-012022-03-310001427570us-gaap:SellingAndMarketingExpenseMember2023-01-012023-03-310001427570us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001427570us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001427570us-gaap:SellingAndMarketingExpenseMember2022-01-012022-03-310001427570us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001427570us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001427570us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001427570rsls:RepresentativesWarrantsMemberrsls:PublicOfferingMember2023-02-082023-02-080001427570rsls:CommonStockWarrantsWithAlternativeCashlessExerciseMemberrsls:PublicOfferingMember2023-02-082023-02-080001427570rsls:CommonStockWarrantsWithAlternativeCashlessExerciseMember2023-02-082023-02-080001427570us-gaap:OverAllotmentOptionMember2023-02-082023-02-080001427570us-gaap:CommonStockMember2023-01-012023-03-310001427570us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001427570us-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2023-04-202023-04-200001427570rsls:BlackScholesModelMember2023-01-012023-03-310001427570rsls:PublicWarrantsMemberrsls:PublicOfferingMember2023-02-082023-02-080001427570rsls:PublicOfferingMember2023-02-082023-02-080001427570us-gaap:CommonStockMemberrsls:PublicOfferingMember2023-02-082023-02-080001427570rsls:PreFundedWarrantsMemberrsls:PublicOfferingMember2023-02-082023-02-080001427570rsls:PublicOfferingMember2023-02-080001427570rsls:CowenAndCompanyLlcMember2021-08-062021-08-060001427570rsls:CowenAndCompanyLlcMember2023-05-112023-05-110001427570rsls:CowenAndCompanyLlcMember2023-05-120001427570rsls:CowenAndCompanyLlcMember2023-05-110001427570rsls:CowenAndCompanyLlcMember2023-03-3100014275702022-01-012022-03-310001427570rsls:PublicOfferingMember2023-01-012023-03-310001427570rsls:CommonStockPurchaseWarrantsMember2023-02-092023-03-310001427570rsls:RepresentativesWarrantsMemberrsls:PublicOfferingMember2023-02-080001427570rsls:PreFundedWarrantsMemberrsls:PublicOfferingMember2023-02-080001427570rsls:CommonStockWarrantsWithAlternativeCashlessExerciseMember2023-01-012023-03-310001427570us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100014275702023-03-3100014275702022-12-3100014275702023-05-1100014275702023-01-012023-03-31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purersls:itemutr:sqftrsls:Y

Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

Commission file number: 1-37897

RESHAPE LIFESCIENCES INC.

(Exact name of registrant as specified in its charter)

Delaware

26-1828101

(State or other jurisdiction
of incorporation or organization)

(IRS Employer
Identification No.)

1001 Calle Amanecer, San Clemente, California 92673
(Address of principal executive offices, including zip code)

(949) 429-6680
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

    

Trading Symbol

Name of Each Exchange on which Registered

Common stock, $0.001 par value per share

RSLS

The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Accelerated Filer

Non-accelerated Filer

  

Smaller Reporting Company

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of May 11, 2023, 2,942,313 shares of the registrant’s Common Stock were outstanding.

Table of Contents

INDEX

PART I – FINANCIAL INFORMATION

Item 1.

Condensed Consolidated Financial Statements (unaudited)

3

Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022

3

Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022

4

Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2023 and 2022

5

Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2023 and 2022

6

Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022

7

Notes to Condensed Consolidated Financial Statements

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

23

Item 4.

Controls and Procedures

23

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

24

Item 1A.

Risk Factors

24

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

24

Item 3.

Defaults Upon Senior Securities

25

Item 4.

Mine Safety Disclosures

25

Item 5.

Other Information

25

Item 6.

Exhibits

26

SIGNATURES

27

2

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1.        CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Balance Sheets

(unaudited)

(dollars in thousands, except per share amounts)

March 31, 

December 31, 

    

2023

    

2022

ASSETS

Current assets:

Cash and cash equivalents

$

8,983

 

$

3,855

Restricted cash

100

100

Accounts and other receivables (net of allowance for doubtful accounts of $444 and $410 respectively)

 

2,125

 

 

2,180

Inventory

 

3,493

 

 

3,611

Prepaid expenses and other current assets

 

530

 

 

165

Total current assets

 

15,231

 

 

9,911

Property and equipment, net

 

672

 

 

698

Operating lease right-of-use assets

86

171

Deferred tax asset, net

57

56

Other intangible assets, net

249

260

Other assets

 

57

 

 

46

Total assets

$

16,352

 

$

11,142

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

1,997

 

$

1,926

Accrued and other liabilities

 

5,319

 

 

5,040

Warranty liability, current

200

344

Operating lease liabilities, current

86

171

Total current liabilities

 

7,602

 

 

7,481

Common stock warrant liability

992

Total liabilities

8,594

 

7,481

Commitments and contingencies (Note 13)

Stockholders’ equity:

Preferred stock, 10,000,000 shares authorized:

Series C convertible preferred stock, $0.001 par value; 95,388 shares issued and outstanding at March 31, 2023 and December 31, 2022

Common stock, $0.001 par value; 300,000,000 shares authorized at March 31, 2023 and December 31, 2022; 2,648,765 and 519,219 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively

 

3

 

 

1

Additional paid-in capital

 

634,697

 

 

627,935

Accumulated deficit

 

(626,849)

 

 

(624,187)

Accumulated other comprehensive loss

(93)

(88)

Total stockholders’ equity

 

7,758

 

 

3,661

Total liabilities and stockholders’ equity

$

16,352

 

$

11,142

See accompanying notes to Condensed Consolidated Financial Statements.

3

Table of Contents

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Operations

(unaudited)

(dollars in thousands, except per share amounts)

Three Months Ended March 31,

2023

    

2022

Revenue

$

2,287

$

2,440

Cost of revenue

 

1,063

 

1,222

Gross profit

 

1,224

 

1,218

Operating expenses:

Sales and marketing

 

2,182

 

4,694

General and administrative

4,220

3,892

Research and development

 

453

 

745

Total operating expenses

6,855

9,331

Operating loss

(5,631)

(8,113)

Other expense (income), net:

Interest expense (income), net

 

5

 

(1)

Gain on changes in fair value of liability warrants

 

(2,965)

 

Gain on foreign currency exchange, net

(21)

(16)

Other

(2)

(11)

Loss before income tax provision

(2,648)

(8,085)

Income tax benefit

14

30

Net loss

$

(2,662)

$

(8,115)

Net loss per share - basic and diluted:

Net loss per share - basic and diluted

(1.56)

(21.87)

Shares used to compute basic and diluted net loss per share

1,708,141

371,031

See accompanying notes to Condensed Consolidated Financial Statements.

4

Table of Contents

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Comprehensive Loss

(unaudited)

(dollars in thousands)

Three Months Ended March 31, 

2023

    

2022

Net loss

$

(2,662)

$

(8,115)

Foreign currency translation adjustments

(5)

21

Other comprehensive income, net of tax

(5)

21

Comprehensive loss

$

(2,667)

$

(8,094)

See accompanying notes to Condensed Consolidated Financial Statements.

5

Table of Contents

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Stockholders’ Equity

(unaudited)

(dollars in thousands)

Three Months Ended March 31, 2023

Series C Convertible

Additional

Accumulated Other

Total

Preferred Stock

Common Stock

Paid-in

Accumulated

Comprehensive

Stockholders’

    

Shares

    

Amount

    

Shares

    

Amount

     

Capital

    

Deficit

    

Loss

     

Equity

Balance December 31, 2022

95,388

$

519,219

$

1

$

627,935

$

(624,187)

$

(88)

$

3,661

Net loss

(2,662)

(2,662)

Other comprehensive income, net of tax

(5)

(5)

Issuance of common stock pursuant to reverse stock split

18,399

Stock compensation

222

222

Common stock purchased

1,185,000

1

1

Equity issuance costs

298

298

Issuance of stock from RSUs

834

Exercise of warrants

925,313

1

6,242

6,243

Balance March 31, 2023

95,388

$

2,648,765

$

3

$

634,697

$

(626,849)

$

(93)

$

7,758

Three Months Ended March 31, 2022

Series C Convertible

Additional

Accumulated

Total

Preferred Stock

Common Stock

Paid-in

Accumulated

Comprehensive

Stockholders’

Shares

    

Amount

    

Shares

    

Amount

     

Capital

    

Deficit

Income (Loss)

     

Equity

Balance December 31, 2021

95,388

$

356,641

$

$

622,399

$

(577,973)

$

(92)

$

44,334

Net loss

(8,115)

(8,115)

Other comprehensive income, net of tax

21

21

Stock compensation

719

719

Issuance of stock from RSUs

15,313

Balance March 31, 2022

95,388

$

371,954

$

$

623,118

$

(586,088)

$

(71)

$

36,959

See accompanying Notes to Condensed Consolidated Financial Statements.

6

Table of Contents

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(dollars in thousands)

Three Months Ended March 31, 

2023

2022

Cash flows from operating activities:

    

Net loss

$

(2,662)

$

(8,115)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation expense

 

37

 

94

Amortization of intangible assets

11

456

Noncash interest expense

Impairment of intangible assets

Loss on extinguishment of debt, net

Loss on disposal of assets, net

Stock-based compensation

222

719

Bad debt expense

34

26

Provision for inventory excess and obsolescence

9

78

Deferred income tax

(1)

Gain on changes in fair value of liability warrants

(2,965)

Offering cost

298

Other noncash items

3

(20)

Change in operating assets and liabilities, net of business combination:

 

 

Accounts and other receivables

 

21

 

379

Inventory

 

108

 

(1,073)

Prepaid expenses and other current assets

 

(365)

 

(137)

Accounts payable and accrued liabilities

344

240

Warranty liability

 

(144)

 

(25)

Other

 

(11)

 

Net cash used in operating activities

(5,061)

(7,378)

Cash flows from investing activities:

Capital expenditures

(7)

(7)

Proceeds from sale of capital assets

9

Cash (used in) provided by investing activities:

(7)

2

Cash flows from financing activities:

Proceeds from sale and issuance of securities

10,201

Net cash provided by financing activities

10,201

Effect of currency exchange rate changes on cash and cash equivalents

 

(5)

 

21

Net increase (decrease) in cash, cash equivalents and restricted cash

 

5,128

 

(7,355)

Cash, cash equivalents and restricted cash at beginning of period

3,955

22,815

Cash, cash equivalents and restricted cash at end of period

$

9,083

$

15,460

Supplemental disclosure:

Cash paid for income taxes

$

$

Cash paid for interest

Noncash investing and financing activities:

Capital expenditures accruals

$

5

$

9

See accompanying notes to Condensed Consolidated Financial Statements.

 

7

Table of Contents

ReShape Lifesciences Inc.

Notes to Condensed Consolidated Financial Statements

(dollars in thousands, except per share amounts; unaudited)

(1)  Basis of Presentation

The accompanying interim condensed consolidated financial statements and related disclosures of Reshape Lifesciences Inc. (the “Company” or “ReShape”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed on April 17, 2023. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted.

In the opinion of management, the interim consolidated condensed financial statements reflect all adjustments considered necessary for a fair statement of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

Reverse Stock Split and Merger Exchange Ratio

On December 23, 2022, at the commencement of trading, the Company effected a 1-for-50 reverse stock split. Accordingly, all share and per share amounts for the periods presented in the accompanying consolidated financial statement and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split. No fractional shares were issued in connection with the reverse stock split.

Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 4 to its audited consolidated financial statements for the year ended December 31, 2022, which are included in the Company’s Annual Report on Form 10-K which was filed with the SEC on April 17, 2023.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may materially differ from these estimates. The Company reviews its estimates on an ongoing basis or as new information becomes available to ensure that these estimates appropriately reflect changes in its business.

Long-Lived Assets

We evaluate long-lived assets, including finite-lived intangible assets, for impairment by comparison of the carrying amounts to future net undiscounted cash flows expected to be generated by such assets when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value or estimates of future discounted cash flows.

Fair Value of Financial Instruments

The carrying amounts of cash equivalents, accounts receivable, accounts payable and certain accrued and other liabilities approximate fair value due to their short-term maturities. Refer to Note 7 regarding fair value measurements and inputs of warrants.

8

Table of Contents

Net Loss Per Share

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

March 31, 

    

2023

    

2022

Stock options

 

18,594

 

16,670

Unvested restricted stock units

3,424

17,987

Convertible preferred stock

10

10

Warrants

 

531,164

 

139,047

Recent Accounting Pronouncements

New accounting standards adopted are discussed below.

In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. In May 2019, the FASB issued ASU No. 2019-05, which amended the new standard by providing targeted transition relief. The new guidance replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. In November 2019, the FASB issued ASU No. 2019-11, which amended the new standard by providing additional clarification. This guidance became effective on January 1, 2023 and did not have a material impact to the consolidated financial statements.

(2)  Liquidity and Management’s Plans

The Company currently does not generate revenue sufficient to offset operating costs and anticipates such shortfalls to continue as the Company has modified its strategy to a metrics-driven approach through a sustainable and scalable business model, via a digital lead generation and re-engagement strategy. As of March 31, 2023, the Company had net working capital of approximately $7.6 million, primarily due to cash and cash equivalents and restricted cash of $9.1 million, and $2.1 million of accounts receivable. On February 8, 2023, the Company completed a public offering, which the Company received approximately $9.4 million in cash and cash equivalents after deducting underwriting expenses, commissions and offering expenses. Based on its available cash resources, the Company may not have sufficient cash on hand to fund its current operations for more than twelve months from the date of filing this Quarterly Report on Form 10-Q. This condition raises substantial doubt about the Company’s ability to continue as a going concern.

The Company’s anticipated operations include plans to (i) grow sales and operations of the Company with the Lap-Band product line both domestically and internationally as well as to obtain cost savings synergies, (ii) introduce to the market place ReShapeCare and ReShape Marketplace as an extension, (iii) marketing efforts to increase brand recognition, create customer awareness and increase the patient demand, (iv) continue development of the DBSN device, (v) seek opportunities to leverage our intellectual property portfolio and custom development services to provide third-party sales and licensing opportunities, and (vi) explore and capitalize on synergistic opportunities to expand our portfolio and offer future minimally invasive treatments and therapies in the obesity continuum of care, including Lap-Band 2.0. The Company believes that it has the flexibility to manage the growth of its expenditures and operations depending on the amount of available cash flows, which could include reducing expenditures for marketing, clinical and product development activities.

The Company may be required to raise additional capital, however, there can be no assurance as to whether additional financing will be available on terms acceptable to the Company, if at all. If sufficient funds on acceptable terms are not available when needed, it would have a negative impact on the Company’s financial condition and could force the Company to delay, limit, reduce, or terminate product development or future commercialization efforts or grant rights to develop and market product candidates or testing products that the Company would otherwise plan to develop.

9

Table of Contents

Therefore, the plans cannot be deemed probable of being implemented. As a result, the Company’s plans do not alleviate substantial doubt about our ability to continue as a going concern.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

COVID-19 Risk

The impact of the COVID-19 outbreak has subsided substantially in the U.S. but continues to result in reduced activity levels outside of the U.S., such as continued restrictions on travel and business operations and advising or requiring individuals to limit or forego their time outside of their homes or places of business.

(3)  Supplemental Balance Sheet Information

Components of selected captions in the condensed consolidated balance sheets consisted of the following:

Inventory:

March 31, 

December 31,

2023

    

2022

Raw materials

$

825

$

832

Sub-assemblies

1,009

864

Finished goods

 

1,659

 

1,915

Total inventory

$

3,493

$

3,611

Prepaid expenses and other current assets:

March 31, 

December 31,

2023

    

2022

Prepaid insurance

$

129

$

78

Patents

92

Prepaid advertising and marketing

71

3

Taxes

70

Other current assets

168

84

Total prepaid expenses and other current assets

$

530

$

165

Accrued and other liabilities:

March 31, 

December 31,

2023

    

2022

Payroll and benefits

$

1,652

$

1,829

Accrued legal settlements

2,025

1,775

Customer deposits

573

510

Taxes

122

119

Accrued professional

602

316

Other liabilities

 

345

 

491

Total accrued and other liabilities

$

5,319

$

5,040

10

Table of Contents

(4) Intangible Assets

The Company’s finite-lived intangible assets consists of developed technology, and trademarks and tradenames. The estimated useful lives of these finite-lived intangible assets is 10 years. The amortization expenses for the three months ended March 31, 2023 and 2022, was $11 thousand and $0.5 million, respectively.

March 31, 2023

    

Weighted Average Useful Life (years)

    

Gross Carrying Amount

    

Accumulated Amortization

    

Net Book Value

Finite-lived intangible assets:

Developed technology

10.0

$

5,989

$

(5,813)

$

176

Trademarks/Tradenames

10.0

462

(389)

73

Total

$

6,451

$

(6,202)

$

249

December 31, 2022

    

Weighted Average Useful Life (years)

    

Gross Carrying Amount

    

Accumulated Amortization

    

Net Book Value

Finite-lived intangible assets:

Developed technology

10.0

$

5,989

$

(5,805)

$

184

Trademarks/Tradenames

10.0

462

(386)

76

Total

$

6,451

$

(6,191)

$

260

(5) Leases

The Company has a noncancelable operating lease for office and warehouse space in San Clemente, which was extended by twelve months with an end date of June 30, 2023. The Company also had an operating lease and warehouse space in Carlsbad, California, which expired June 30, 2022. On March 13, 2023, the Company entered into a lease for approximately 5,038 square feet of office and warehouse space at 18 Technology Drive, Suite 110, Irvine California 92618 and intend to relocate our principal executive offices from our current San Clemente, California location to the Irvine, California location. The Irvine California lease has a term of 36 months commencing on May 1, 2023.

The Company does not have any short-term leases or financing lease arrangements. Lease and non-lease components are accounted for separately.

Operating lease costs were $0.1 million and $0.2 million for the three months ended March 31, 2023 and 2022, respectively. Variable lease costs were not material.

Supplemental information related to operating leases is as follows:

March 31,

December 31,

Balance Sheet information

2023

2022

Operating lease ROU assets

$

86

$

171

Operating lease liabilities, current portion

$

86

$

171

Total operating lease liabilities

$

86

$

171

Cash flow information for the three months ended March 31,

2023

2022

Cash paid for amounts included in the measurement of operating leases liabilities

$

87

$

200

11

Table of Contents

Maturities of operating lease liabilities were as follows:

2023

87

Total lease payments

87

Less: imputed interest

1

Total lease liabilities

$

86

Weighted-average remaining lease term at end of period (in years)

0.3

Weighted-average discount rate at end of period

5.1

%

(6)  Equity

Common Stock Issued Related to Restricted Stock Units

During the three months ended March 31, 2023 and 2022, the Company issued 834 shares of common stock and 16,265 shares of common stock, respectively, subject to vesting of the restricted stock units. For further details see Note 10.

February Public Offering of Common Stock and Warrants

On February 8, 2023, the Company closed a public offering of 1,275,000 units, with each consisting of one share of its common stock, or one pre-funded warrant to purchase one share of its common stock, and one warrant to purchase one and one-half shares of its common stock. Each unit was sold at public offering price of $8.00. The warrants in the units are immediately exercisable at a price of $8.00 per share and expire five years from the date of issuance. Alternatively, each warrant can be exercised pursuant to the “alternative cashless exercise” provision, to which the holders would receive an aggregate number of shares of common stock equal the product of (x) the aggregate number of shares of common stock that would be issuable upon a cash exercise and (y) 0.50. For purposes of clarity, one common warrant to purchase one and one-half shares would be exercisable for 0.75 shares under this alternative cashless exercise provision. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants were only purchasable together in this offering but were issued separately and immediately separable upon issuance. As of March 31, 2023, warrants to purchase 1,670,626 shares of common stock have been exercised under the alternative cashless exercise for a total of 835,313 shares of common stock.

Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately $10.2 million. The Company intends to use the net proceeds of this offering to continue implementation of its growth strategies, for working capital and general corporate purposes.

The Company also granted the underwriters an option to purchase an additional 191,250 shares of common stock and/or additional warrants to purchase up to 286,875 shares of common stock, to cover over-allotments, of which Maxim Group LLC exercised its option to purchase additional warrants to purchase 286,875 shares of common stock.

(7) Warrants

On February 8, 2023, the Company completed a public offering in which three classes of warrants were issued. There were 2,199,375 common stock purchase warrants issued with an alternative cashless exercise provision. The alternative cashless exercise allows the holder to exercise one warrant share for 0.5 shares of common stock or exercise via the cash exercise price of $8.00 per share of common stock per warrant. These warrants we classified as a liability, and the Company utilized a bifurcated Black-Scholes option pricing model to consider the cash exercise option and cashless exercise option. The bifurcated Black-Scholes option pricing model used an exercise price where the two exercise methods would be indifferent with market inputs of the stock price on the issuance, risk free interest rate, expected share price volatility and dividend yield. The Company calculates the fair value of the warrants at each reporting period and when a warrant is exercised, with the changes in fair value recognized in the statement of operations. Below is a summary of the initial inputs used in the bifurcated Black-Scholes option pricing model.

12

Table of Contents

Cash Exercise

Cashless Exercise

Stock Price

$

5.905

$

5.905

Exercise Price

$

16.00

$

0.00

Term (years)

5.00

5.00

Volatility

96.50%

96.50%

Risk Free Rate

3.784%

3.784%

Dividend Yield

0%

0%

The following table presents the changes in the fair value of warrant liabilities:

Common Stock

Purchase Warrants

Fair value as of February 8, 2023 (issuance date)

$

10,363

Exercises of liability warrants

(6,242)

Gain on changes in fair value of liability warrants

(3,129)

Fair value as of March 31, 2023

$

992

In addition, one of the investors purchased 90,000 pre-funded warrants at a price of $7.999 per warrant. These warrants have an exercise price of $0.0001 per share and do not expire. The pre-funded warrants were valued at $0.5 million using the fair value approach at the time of issuance. The fair value of the pre-funded warrants was determined using a Black Scholes option pricing model using a risk free rate of 3.784%, an expected term of 5.0 years, expected dividends of zero and expected volatility of 96.5%.

As part of the terms of the offering the Company issued 73,313 representative’s warrants with an exercise price of $8.80 per share and expiration date on February 3, 2028. The representative’s warrants were valued at $ $0.3 million using the fair value approach at the time of issuance. The fair value of the representative’s warrants was determined using a Black Scholes option pricing model using a risk free rate of 3.786%, an expected term of 4.99 years, expected dividends of zero and expected volatility of 96.5%.

(8) Revenue Disaggregation and Operating Segments

The Company conducts operations worldwide and has sales in the following regions: United States, Australia, Europe and Rest of World. For the three months ended March 31, 2023 and 2022, the Company primarily only sold the Lap-Band system. The following table presents the Company’s revenue disaggregated by geography:

Three Months Ended

March 31, 

    

2023

    

2022

United States

$

1,813

$

1,844

Australia

157

181

Europe

304

414

Rest of world

13

1

Total revenue

$

2,287

$

2,440

Operating Segments

The Company conducts operations worldwide and is managed in the following geographical regions: United States, Australia, Europe and the Rest of World (primarily in the Middle East). All regions sell the Lap-Band system, which consisted of nearly all our revenue and gross profit for the three months ended March 31, 2023 and 2022. During the three months ended March 31, 2023 and 2022, there was minimal revenue for ReShapeCare. There was no revenue or gross profit recorded for the DBSN device for the three months ended March 31, 2023 and 2022 as this product is still in the development stage. There was also no revenue recorded for the Obalon line.

13

Table of Contents

(9) Income Taxes

During the three months ended March 31, 2023 and March 31, 2022, the Company recorded income tax expense of $14 thousand and $30 thousand, respectively, related to minimum state taxes and projected Australian and Netherlands income, respectively. The income tax provisions for the three months ended March 31, 2023, were calculated using the discrete year-to-date method. The effective tax rate differs from the statutory tax rate of 21% primarily due to the existence of valuation allowances against net deferred tax assets and current liabilities resulting from the estimated state income tax liabilities and foreign tax liability.

In assessing the realization of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Based on the level of historical losses, projections of losses in future periods and potential limitations pursuant to changes in ownership under Internal Revenue Code Section 382, the Company provided a valuation allowance at both March 31, 2023 and December 31, 2022.

(10)  Stock-based Compensation

Stock-based compensation expense related to stock options and RSUs issued under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan (the “Plan”) for the three months ended March 31, 2023 and 2022 were as follows:

Three Months Ended

March 31, 

2023

2022

Sales and marketing

$

30

$

91

General and administrative

128

557

Research and development

64

71

Total stock-based compensation expense

$

222

$

719

Stock Options

A summary of the status of the Company’s stock options as of March 31, 2023, and changes during the three months ended March 31, 2023 are as follows:

    

Weighted

Weighted

Average

Aggregate

Average

Remaining

Intrinsic

    

Exercise Price

Contractual

Value

Shares

Per Share

Life (years)

(in thousands)

Outstanding at December 31, 2022

 

21,416

311.65

$

Options granted

 

Options exercised

 

Options cancelled

 

(2,822)

144.38

Outstanding at March 31, 2023

 

18,594

337.03

7.7

$

Exercisable at March 31, 2023

13,314

435.38

7.3

Vested and expected to vest at March 31, 2023

18,594

337.03

7.7

There was no intrinsic value of the outstanding stock options at March 31, 2023. The unrecognized share-based expense at March 31, 2023 was $0.3 million, and will be recognized over a weighted average period of 2.3 years.

Stock option awards outstanding under the Company’s incentive plans have been granted at exercise prices that are equal to the market value of its common stock on the date of grant. Such options generally vest over a period of four years and expire at ten years after the grant date. The Company recognized compensation expense ratably over the vesting period. The Company uses a Black-Scholes option-pricing model to estimate the fair value of stock options granted, which requires the input of both subjective and objective assumptions as follows:

14

Table of Contents

Expected Term – The estimate of expected term is based on the historical exercise behavior of grantees, as well as the contractual life of the options granted.

Expected Volatility – The expected volatility factor is based on the volatility of the Company’s common stock for a period equal to the term of the stock options.

Risk-free Interest Rate – The risk-free interest rate is determined using the implied yield for a traded zero-coupon U.S. Treasury bond with a term equal to the expected term of the stock options.

Expected Dividend Yield – The expected dividend yield is based on the Company’s historical practice of paying dividends on its common stock.

Restricted Stock Units

A summary of the Company’s unvested RSUs award activity for the three months ended March 31, 2023, is as follows:

Weighted

Average

    

Grant Date

Shares

Fair Value

Unvested RSUs at December 31, 2022

 

4,544

$

174.15

Granted

 

Vested (1)

 

(1,112)

196.26

Cancelled/Forfeited

 

Non-vested RSUs at March 31, 2023

 

3,432

166.99

(1)At March 31, 2023, there were 278 shares of common stock related to RSU awards that had vested and the shares were not distributed to the participants until April of 2023.

The fair value of each RSU is the closing stock price on the Nasdaq of the Company’s common stock on the date of grant. Upon vesting, a portion of the RSU award may be withheld to satisfy the statutory income tax withholding obligation. The remaining RSUs will be settled in shares of the Company’s common stock after the vesting period. The unrecognized compensation cost related to the RSUs at March 31, 2023 was $0.6 million and expected to be recognized over a period of 1.4 years.

(11)  Commitment and Contingencies

Litigation

On August 6, 2021, Cowen and Company, LLC filed a complaint against ReShape, as successor in interest to Obalon Therapeutics, in the Supreme Court of the State of New York based on an alleged breach of contract arising out of Cowen’s prior engagement as Obalon’s financial advisor. The complaint alleges that Cowen is entitled to be paid a $1.35 million fee in connection with ReShape’s merger with Obalon under the terms of Cowen’s engagement agreement with Obalon. The complaint also seeks reimbursement of Cowen’s attorneys’ fees and interest in connection with its claim. On May 11, 2023, the Supreme Court of the State of New York issued the final judgement in favor of Cowen & Company in the amount of $1.35 million, plus interest at the statutory rate of 9% per annum from June 16, 2021 until judgement is paid in full, and reimbursement of $675,000 of Cowen’s attorneys’ fees, with $275,000 to be paid upfront, $200,000 paid after six months and $200,000 paid after 12 months, subject to the final order of the Court. The Company has accrued the $1.35 million, for the ruling, $0.7 million for the attorneys’ fees, and $0.2 million of accrued interest at March 31, 2023, and paid the first installment of $1.9 million on May 12, 2023.

The Company is not aware of any pending or threatened litigation against it that could have a material adverse effect on the Company’s business, operating results or financial condition, other than what was disclosed above. The medical device industry in which the Company operates is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property rights as well as improper hiring practices. As a result, the Company may be involved in various legal proceedings from time to time.

15

Table of Contents

Product Liability Claims

The Company is exposed to product liability claims that are inherent in the testing, production, marketing and sale of medical devices. Management believes any losses that may occur from these matters are adequately covered by insurance, and the ultimate outcome of these matters will not have a material effect on the Company’s financial position or results of operations. The Company is not currently a party to any product liability litigation and is not aware of any pending or threatened product liability litigation that is reasonably possible to have a material adverse effect on the Company’s business, operating results or financial condition.

(12) Subsequent Events

On April 20, 2023, ReShape Lifesciences Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor in a registered direct offering (the “Registered Offering”) (i) 291,395 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) pre-funded warrants to purchase an aggregate of 509,300 shares of Common Stock (the “Pre-funded Warrants”). Each share of Common Stock was sold at a price of $3.07 per share and each Pre-funded Warrant was sold at an offering price of $3.069 per share underlying such Pre-funded Warrants, for aggregate gross proceeds of approximately $2.5 million before deducting the placement agent’s fees and the offering expenses. Under the Purchase Agreement, the Company also agreed to issue and sell to the Investor in a concurrent private placement (the “Private Placement,” and together with the Registered Offering, the “Offering”) warrants to purchase an aggregate of 800,695 shares of Common Stock (the “Common Warrants,” and together with the Prefunded Warrants, the “Warrants”).

In connection with the Offering, the Company also agreed that certain existing warrants to purchase up to an aggregate of 164,656 shares of Common Stock that were issued to the Investor, at an exercise price of $15.00 per share, were amended effective upon the closing of the Offering so that the amended warrants have an exercise price of $3.07.

The Company’s exclusive placement agent in connection with the Offering, Maxim Group LLC, received a cash fee equal to 7.0% of the gross proceeds received by the Company from the sale of the securities in Offering, as well as reimbursement for certain expenses, and warrants to purchase up to 40,035 shares of Common Stock, which is equal to 5.0% of the aggregate amount of shares of Common Stock (or Common Stock equivalents in the form of Pre-funded Warrants) issued in the Offering, at an exercise price of $3.38 per share.

The Offering closed on April 24, 2023.

16

Table of Contents

ITEM  2.       MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 

The following discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q. 

Except for the historical information contained herein, the matters discussed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” are forward-looking statements that involve risks and uncertainties. In some cases, these statements may be identified by terminology such as “may,” “will,” “should,” “expects,” “could,” “intends,” “might,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of such terms and other comparable terminology. These statements involve known and unknown risks and uncertainties that may cause our results, level of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Factors that may cause or contribute to such differences include, among others, those discussed in the “Risk Factors” section included in Item 1A of our most recent Annual Report on Form 10-K. 

Except as may be required by law, we undertake no obligation to update any forward-looking statement to reflect events after the date of this report. 

Overview

We are the premier global weight-loss solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and associated metabolic disease. Our primary operations are in the following geographical areas: United States, Australia and certain European and Middle Eastern countries. Our current portfolio includes the Lap-Band Adjustable Gastric Banding System, the ReShapeCare virtual health coaching program, the ReShape Marketplace, the Obalon Balloon System, and the Diabetes Bloc-Stim Neuromodulation device, a technology under development as a new treatment for type 2 diabetes mellitus. There has been no revenue recorded for the Obalon Balloon System, and there has been no revenue recorded for the Diabetes Bloc-Stim Neuromodulation as this product is still in the development stage.

Recent Developments

On March 13, 2023 we entered into a lease for approximately 5,038 square feet of office/warehouse space at 18 Technology Drive, Suite 110, Irvine, California 92618 and intend to relocate our principal executive offices from our current San Clemente, California location to the Irvine, California location. The Irvine California lease has a term of 36 months commencing on May 1, 2023.

17

Table of Contents

Results of Operations

The following table sets forth certain data from our unaudited consolidated statements of operations expressed as percentages of revenue (in thousands):

Three Months Ended March 31, 

2023

2022

Revenue

$

2,287

100.0

%

$

2,440

100.0

%

Cost of revenue

1,063

46.5

%

1,222

50.1

%

Gross profit

1,224

53.5

%

1,218

49.9

%

Operating expenses:

Sales and marketing

2,182

95.4

%

4,694

192.4

%

General and administrative

4,220

184.5

%

3,892

159.5

%

Research and development

453

19.8

%

745

30.5

%

Total operating expenses

6,855

299.7

%

9,331

382.4

%

Operating loss

(5,631)

(246.2)

%

(8,113)

(332.5)

%

Other expense (income), net:

Interest expense (income), net

5

0.2

%

(1)

%

Gain on changes in fair value of liability warrants

(2,965)

(129.6)

%

%

Gain on foreign currency exchange, net

(21)

(0.9)

%

(16)

(0.7)

%

Other

(2)

(0.1)

%

(11)

(0.5)

%

Loss before income tax provision

(2,648)

(115.8)

%

(8,085)

(331.4)

%

Income tax benefit

14

0.6

%

30

1.2

%

Net loss

$

(2,662)

(116.5)

%

$

(8,115)

(332.6)

%

Non-GAAP Disclosures

In addition to the financial information prepared in conformity with GAAP, we provide certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results.

Management believes that the presentation of this non-GAAP financial information provides investors with greater transparency and facilitates comparison of operating results across a broad spectrum of companies with varying capital structures, compensation strategies, and amortization methods, which provides a more complete understanding of our financial performance, competitive position, and prospects for the future. However, the non-GAAP financial measures presented in the Form 10-Q have certain limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

Adjusted EBITDA

Management uses adjusted EBITDA in its evaluation of the Company’s core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, stock-based compensation, and other one-time costs.

18

Table of Contents

The following table contains a reconciliation of GAAP net loss to Adjusted EBITDA net loss attributable to common stockholders for the months ended March 31, 2023 and 2022 (in thousands):

Three Months Ended March 31, 

2023

2022

GAAP net loss

$

(2,662)

$

(8,115)

Adjustments:

Interest expense (income), net

5

(1)

Income tax benefit

14

30

Depreciation and amortization

48

550

Stock-based compensation expense

222

719

Gain on changes in fair value of liability warrants

(2,965)

Adjusted EBITDA

$

(5,338)

$

(6,817)

Comparison of Results of Operations

Three months ended March 31, 2023 and March 31, 2022

Revenue. The following table summarizes our unaudited revenue by geographic location based on the location of customers for the three months ended March 31, 2023 and 2022, as well as the percentage of each location to total revenue and the amount of change and percentage of change (dollars in thousands):

Three Months Ended March 31, 

Amount

Percentage

2023

2022

Change

Change

United States

$

1,813

79.3

%

$

1,844

75.6

%

$

(31)

(1.7)

%

Australia

157

6.9

%

181

7.4

%

(24)

(13.3)

%